Emerging treatments in type 2 diabetes: focus on canagliflozin
Marek Rosiak,1,2 Susanna Grzeszczak,2 Dariusz A Kosior,2,3 Marek Postuła1,2 1Department of Cardiology and Hypertension, Central Clinical Hospital, the Ministry of the Interior, Warsaw, Poland; 2Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland; 3Mossakowski M...
Main Authors: | Rosiak M, Grzeszczak S, Kosior DA, Postuła M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-08-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/emerging-treatments-in-type-2-diabetes-focus-on-canagliflozin-peer-reviewed-article-TCRM |
Similar Items
-
SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014-01-01) -
Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
by: Curtis Triplitt, et al.
Published: (2015-01-01) -
Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
by: Curtis Triplitt, et al.
Published: (2015-10-01) -
Canagliflozin: a novel treatment option for type 2 diabetes
by: Dietrich E, et al.
Published: (2013-11-01) -
SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
by: Seufert J
Published: (2015-11-01)